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Aging hearts are known to have diminished capacity to be 
protected against reoxygenation ischemia/reperfusion (IR) injury 
provided  by  various  cardioprotective  regimens.  In  search  of  a 
more successful regimen, we have studied the response of aged 
hearts to preconditioning (PC) and postconditioning (POST) 
elicited by sphingosine or sphingosine 1-phosphate treatment.
An ex vivo rat heart model was used to study the ability of PC 
and POST to protect old hearts (27 month) against I/R injury 
generated by 40 minutes (min) of index ischemia followed by 40 
min of reperfusion. The response to ischemic PC was reduced 
in 27 month old hearts relative to 3–6 month (young) hearts as 
noted by a poor recovery of left ventricular developed pressure 
(LVDP) upon reperfusion (45% vs. 74% in young hearts) and 
a large infarct size after 40 min of reperfusion (37% versus 8% 
in young hearts). PC with sphingosine 1-phosphate (S1P) was 
also poor in old hearts yielding only 49% recovery of LVDP and 
a 27% infarct size. In contrast, PC with sphingosine was unaf-
fected by aging; the 78% recovery of LVDP and 8% infarct size 
were not different from young hearts. Ischemic POST was less 
affected by aging than ischemic PC, but the old hearts still expe-
rienced infarct sizes of 28%. POST of old hearts with S1P was 
also associated with a substantial infarct size (24%). However, 
POST of old hearts with sphingosine was superior to the other 
forms of POST in that it reduced the infarct size to 12%. S1P 
levels were found to be lower in old hearts which may contribute 
to the decreased effectiveness of ischemic PC and POST. Further, 
phospho-Akt levels and distribution were altered in response to 
cardioprotection in the old hearts. In conclusion, POST was less 
affected by aging than PC; and sphingosine is a uniquely effective 
agent for both PC and POST of aging hearts.
Introduction
The loss of coronary blood flow for an extended period of time 
leads  to  ischemic  damage  and  cardiomyocyte  death.  However, 
ischemic tissues must be exposed to molecular oxygen on reperfu-
sion to manifest tissue injury.1,2 This strongly implicates reactive 
oxygen species in the injury process.1,2 This effect has been termed 
IR injury. Reoxygenation IR injury is a major complication of 
acute  ischemia/infarction,  cardiopulmonary  bypass,  angioplasty 
and heart transplantation.3 However, hearts can be treated (“condi-
tioned”) in such a way that the damage associated with ischemia 
and subsequent reoxygenation is greatly diminished.4,5 Ischemic 
preconditioning consists of one or more cycles of a short-term 
non-damaging period of ischemia followed by reperfusion initiated 
prior to the extended index ischemia and subsequent reperfusion. 
This  prevents  loss  of  myocardial  function  and  reduces  subse-
quent  infarct  size.4,5 This  same  treatment  can  also  be  initiated 
after the index ischemia just prior to full reperfusion with equal 
effectiveness.6 This is referred to as postconditioning. A variety of 
pharmacologic agents can also serve as pre- and post-conditioning 
agents.
Studies in animals and humans have shown that aging hearts 
have reduced resistance to IR injury7-9 and a reduced capacity to 
be preconditioned.9 This includes both ischemic preconditioning 
as  well  as  pharmacologic  preconditioning.9  It  should  be  noted 
that the cardioprotective effect of preconditioning has been shown 
to be impaired with aging in humans.9 Recent studies have indi-
cated that post-conditioning regimens are also compromised with 
aging.10,11
We  were  interested  in  examining  the  effectiveness  of  sphin-
golipid signaling pathways during pre- and post-conditioning of 
aging hearts. The lipid mediator S1P is known to be a potent 
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cardiac pre- and post-conditioning agent.12-16 Further, the enzyme 
SKase  that  catalyzes  its  synthesis  has  also  been  shown  to  be   
important in pre- and post-conditioning.17-19 Recently, we found 
that sphingosine also is a potent pre- and post-conditioning agent 
and that it accomplishes this via a different and complementary 
pathway from that of S1P.15,16 In this paper we have examined the 
effectiveness of both S1P and sphingosine in protecting the aging 
heart from reoxygenation injury.
Results
For these studies, we used the Langendorff isolated perfused 
heart model. We compared hearts from young rats (3–6 months) 
with hearts from approximately 27-month-old rats (range 26–28 
months). The  baseline  heart  rates  and  coronary  flow  rates  for 
isolated perfused hearts were more variable in older rats but not 
different on average from young hearts. Contractile function was 
slightly  elevated  for  aged  hearts  (LVDP  128  ±  9  versus  115  ± 
4 mm Hg in young hearts).
We wanted to verify that in our system aged rat hearts have 
a  deficient  response  to  ischemic  pre-  and  post-conditioning.   
We first investigated ischemic preconditioning (IPC). We attempted 
to  protect  the  27-month  hearts  from  ischemia/reperfusion   
injury using the standard IPC regimen19 of two cycles of 4 min 
ischemia/6 min reperfusion. The data in Table 1 reveal that the 
recovery of LVDP was only 45 ± 10% and the infarct size was large 
(37 ± 12%). While this recovery of LVDP was highly significantly 
better (p < 0.001) than untreated old hearts (10 ± 5% LVDP), 
the infarct size was not statistically different (p > 0.1) from that 
of untreated hearts (44 ± 2). IPC was not completely effective in 
old rats. In contrast, hearts from young rats (3- to 6-months-old) 
responded to IPC with 74 ± 5% recovery of LVDP and only a 8 ± 
2% infarct size. The differences in response to IPC between young 
and old rats was highly significant (p < 0.02) for both LVDP and 
infarct size.
The response of old hearts to pharmacologic preconditioning 
with  S1P  or  sphingosine  has  not  previously  been  investigated. 
Preconditioning of 27 month hearts with 0.2 μM S1P (Table 1) 
was marginally effective. There was a 49 ± 13% recovery of LVDP 
but  a  sizeable  infarct  size  (27  ±  11%).  Using  S1P  at  a  higher 
concentration (0.4 μM) was less successful (48 ± 10% recovery 
of LVDP and 39 ± 6% infarct size). However, by comparison, 
for young hearts S1P gave rise to 72 ± 8% recovery of LVDP 
with almost no areas of infarction (6 ± 1% infarct size). Thus, 
aged  hearts  are  significantly  (p  <  0.05)  less  responsive  to  S1P 
than young hearts. The most effective preconditioning agent was 
D-erythro-sphingosine (sphingosine). Preconditioning 27-month-
old hearts with 0.2 μM sphingosine (the optimum concentration) 
resulted in 78 ± 11% recovery of LVDP with only an 8 ± 1% 
infarct size. This is equivalent to the protection obtained in young 
hearts (Table 1).
We  next  examined  ischemic  postconditioning  (IPOST).   
This  was  accomplished  by  instituting  four  cycles  of  15  sec   
ischemia/15 sec reperfusion immediately after the index ischemia 
just prior to full reperfusion. The level of protection achieved by 
IPOST was poor in the old rats. The recovery of LVDP was lower 
in old hearts (57 ± 15% with old hearts versus 70 ± 7% with 
young hearts) though not significantly so (p = 0.1). Old hearts   
had significantly (p = 0.02) larger infarct sizes (28 ± 7% with old 
hearts versus 11 ± 5% with young hearts).
Postconditioning with 0.2 μM S1P resulted in significantly 
reduced  (p  =  0.036)  recovery  of  LVDP  relative  to  young 
hearts (65 ± 7% in old hearts as opposed to 80 ± 9% in young   
hearts), and highly significantly larger (p < 0.001) infarct sizes   
(24 ± 2% versus 8 ± 2% in young hearts). As with precondi-
tioning,  0.2  μM  sphingosine  (the  optimum  concentration) 
proved to be the most effective treatment for postconditioning 
old  hearts.  It  provided  good  recovery  of  hemodynamic  func-
tion (68 ± 8% recovery of LVDP) and had a very significantly   
(p < 0.004) smaller infarct size (12 ± 4%) compared to IPOST 
(28 ± 7%) and S1P (24 ± 2%). In fact, both the LVDP and the 
infarct sizes with sphingosine postconditioning of aged hearts are 
almost as good as the response in young hearts (75 ± 8% recovery 
of LVDP and 11 ± 7% infarct size).
We sought to determine the basis for the diminished response 
of aged hearts to ischemic pre- and post-conditioning. Because 
S1P  has  proved  to  be  an  important  endogenous  cardiopro-
tectant  (see  Introduction),  we  compared  S1P  levels  between   
27-month-old  rats  and  6-month-old  rats  (Table  2). There  was 
a trend (p = 0.07) toward reduction in S1P levels in old hearts   
(82 ± 32 versus 117 ± 6 ng/g dry wt), though there was great 
variability  in  the  S1P  levels  for  old  hearts. These  data  suggest   
that hearts from most aged rats have reduced levels of S1P.
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Table 1  Effect of age on pre- and post-conditioning
              3 months                28 months 
Treatment  LVDP  Infarct size  LVDP  Infarct size
No Treatment  8 ± 3  45 ± 1  10 ± 5  44 ± 2
Isc Pre-C  74 ± 5  8 ± 2  45 ± 10  37 ± 12
Isc Post-C  70 ± 7  11 ± 5  57 ± 15  28 ± 7
S1P Pre-C  72 ± 8  6 ± 1  49 ± 13  27 ± 11
S1P Post-C  80 ± 9  8 ± 2  65 ± 7  24 ± 2
Sph Pre-C  76 ± 7  7 ± 3  78 ± 11  8 ± 1
Sph Post-C  75 ± 8  11 ± 7  68 ± 8  12 ± 4
Ex vivo hearts from 3 month and 28 month old rats were exposed to 20 min of equilibration or precon-
ditioning, 40 min of ischemia, and then 40 min of reperfusion. The recovery of left ventricular developed 
pressure (LVDP) upon reperfusion is expressed as % of the preischemic value.  Infarct size (as % of the 
risk area) was determined at the end of 40 min of reperfusion. The data are presented as the mean ± 
standard deviation (n ≥ 4).
Table 2    Level of S1P and SKase in hearts from harlan 
F-344 rats
Heart  S1P (ng/g wet wt. heart)  SKase (pmol/min/g wet wt.)
27 Month  82 ± 32  155 ± 6
6 Month  117 ± 6  152 ± 20
Rat heart homogenates were analyzed for S1P content and SKase activity as indicated in Methods. There 
was an n of 4 for each.Sphingosine protects aging hearts
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both  S1P  and  sphingosine  supported  recovery  of 
phospho-Akt  levels  during  reperfusion  of  young 
hearts (Fig. 2). In 27 month old hearts, a reduced 
recovery of phospho-Akt in the cytosol was noted 
for both S1P and sphingosine postconditioning, and 
this was accompanied by an increase in phospho-
Akt in the particulate fraction (Fig. 2). However, 
ischemic postconditioning was not associated with 
phospho-Akt in the particulate fractions of either 
young or old hearts, which is clearly different from 
sphingosine and S1P postconditioning.
Discussion
Previous  work  revealed  that  aging  results  in  a 
loss  of  responsiveness  to  a  number  of  cardiopro-
tectants.7-11,22 Using an ex vivo rat heart model,   
we have also found that ischemic pre- and post-
conditioning is less effective in 27-month-old rats 
relative to 3- to 6-month-old rats. This was particu-
larly true for ischemic preconditioning of old hearts 
which  did  not  prevent  the  development  of  large 
infarct sizes (37 ± 12%). It was surprising that the 
LVDP recovered as well as it did in the old hearts 
(45  ±  10%)  considering  the  magnitude  of  the 
infarcts.  Ischemic  postconditioned  hearts  recover 
somewhat  better  than  ischemic  preconditioned 
hearts but still had infarct sizes of 28 ± 7%, which 
is much greater than for young hearts (11 ± 5%). Thus, while   
ischemic post-conditioning is less affected by age, it still didn’t 
prevent  development  of  significant  areas  of  infarction  in  aged 
hearts.
The response of old hearts to pharmacologic preconditioning 
with S1P was nearly the same as ischemic preconditioning. There 
was a fairly modest recovery of LVDP (49 ± 13%) that was much 
less than in young hearts, but more importantly there were notable 
areas of infarction (27 ± 11%). By contrast, preconditioning with 
sphingosine  appeared  to  be  little  affected  by  age.  Sphingosine 
preconditioning gave rise to 78 ± 11% recovery of LVDP with 
infarct sizes of only 8 ± 1%. This is equivalent protection to that 
obtained with young hearts. Thus, sphingosine appears to be an 
effective  preconditioning  agent  in  aged  hearts.  Preconditioning 
with sphingosine had previously been shown to operate via a PKA 
and PKG dependent pathway while S1P operates via a GPCR 
pathway.15 This suggests that cyclic nucleotide-dependent path-
ways are less affected by age than are GPCR coupled pathways. 
The  GPCR  pathways  have  been  shown  to  involve  the  activa-
tion of PI3 kinase, Akt and protein kinase C (PKC).11,15 PKC   
content and activation by translocation have been shown to be 
diminished  with  age.11  This  could  account  for  the  decreased   
effectiveness with age of GPCR linked cardioprotection pathways. 
By contrast, sphingosine signaling is independent of PKC,15 and 
this may in part account for its sustained effectiveness with age.
Postconditioning  was  also  affected  by  aging  but  to  a  lesser 
extent  than  preconditioning.  Ischemically  postconditioned  old 
hearts  showed  substantial  hemodynamic  recovery  (57  ±  15% 
recovery of LVDP) but with sizable infarcts (28 ± 7% of risk area). 
We next measured SKase activity in these hearts. SKase is not 
only the enzyme responsible for S1P synthesis but its activity has 
been shown to be critical to both pre- and post-conditioning.17,18 
Surprisingly the SKase activity was not significantly different in 
the 27 month hearts (155 ± 6 pmol/min/mg) as compared with 6 
month hearts (152 ± 20 pmol/min/mg).
Although  total  SKase  activity  didn’t  change  with  aging,  a 
surprising finding was a very dramatic change with age in the ratio 
of SK1 to SK2 in the cytosolic fraction (the predominant location 
of SKase in rat heart19). In 6 month old hearts (as with 3 month 
old hearts21), SK2 is the predominant form comprising 63 ± 2% 
(n = 4) of the total activity (measured either by the area under the 
curve for each peak or in pooled fractions). In 28 month old hearts 
this ratio is reversed with SK1 comprising 60 ± 4% (n = 4) of the 
total activity. Thus, SK1 activity nearly doubles with aging while 
SK2 activity is halved. A representative example of the separation 
of SK1 and SK2 form young and old rats is shown in Figure 1.
We also examined the responsiveness of signaling pathways to 
pre- and post-conditioning in old versus young hearts. We previ-
ously  demonstrated  that  pre-  and  post-conditioning  in  young 
hearts by both S1P and sphingosine was associated with high levels 
of phospho-Akt in the cytosolic fraction during reperfusion.15,16 
Therefore, we compared the levels of phospho-Akt during reperfu-
sion for old versus young hearts. Preconditioning with ischemia, S1P 
or sphingosine supported relatively higher levels of phospho-Akt in 
the cytosol of young hearts after 40 min of reperfusion as compared 
to old hearts (Fig. 2). For pharmacologic preconditioning with S1P, 
this appeared to be in part due to retention of phospho-Akt in the 
particulate fraction (Fig. 2). For pharmacologic postconditioning, 
Figure 1. Gel Filtration Profile of Cytoslic SKase Activity from Young and Old Rat Hearts. 
The cytosolic fractions isolated from 6-month-old (-●-) and 27-month-old (-○-) rat hearts were 
chromatographed on a Sephacryl S200 gel filtration column. The fractions were assayed 
for SKase activity as described in Methods. The profile is representative of four separate 
experiments. The identification of the SK1 and SK2 peaks was described previously (Vessey 
et al. 2007).www.landesbioscience.com Oxidative Medicine and Cellular Longevity 149
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signaling  pathways.15,17,27,28  While  phospho-Akt  is  known  to 
have anti-apoptotic effects, it also has other pro-survival effects 
that are more important for protection during the early period of 
  reperfusion. Signs of apoptosis do not appear until after several 
hours  of  reperfusion.17  Protection  by  phospho-Akt  during  the 
early phase of reperfusion is likely due to stabilization of mito-
chondria29 with a resultant decrease in the formation of reactive 
oxygen species.
When  phospho-Akt  levels  were  measured  during  reperfu-
sion, it was found for both ischemic preconditioning as well as 
pharmacologic  preconditioning  with  S1P  or  sphingosine  that 
the phospho-Akt level was lower in the cytosolic fraction of old 
hearts relative to young hearts. This indicates clearly that the Akt 
signaling pathway is altered with aging. However, in contrast to 
changes in the cytosolic fraction, for S1P pre- and post-condi-
tioning,  the  phospho-Akt  levels  in  the  particulate  fraction  of   
old  hearts  were  increased  relative  to  that  for  young  hearts.   
The  same  was  true  for  sphingosine  postconditioning.  Whether 
these shifts of phospho-Akt from the cytosolic to the particulate 
fraction impacts protection is not yet known. Interestingly, for 
IPOST there was no phospho-Akt detectable in the particulate 
fraction for either young or old hearts. This suggests that reten-
tion of phospho-Akt in the particulate fraction is not essential for 
cardioprotection.
Alterations  in  receptor  sensitivity  and  Akt  phosphoryla-
tion  with  aging  have  been  reported  for  adenosine  mediated 
signaling pathways22 but not such a cytosol to particulate shift in   
phospho-Akt.  Studies  in  ex  vivo  mouse  heart  suggested  that  a 
deficit  in  ERK  phosphorylation  contributed  to  a  loss  of  post-
conditioning in old mouse hearts,11 but we have not found ERK 
phosphorylation to be a key factor in cardioprotection in rat heart. 
Clearly though there are alterations in the signaling mechanism 
with aging.
Postconditioning  with  S1P  gave  similar 
results (65 ± 7% recovery of LVDP but 24 
± 2% infarct size). However, sphingosine 
protection  again  proved  to  be  relatively 
unaffected by age. Postconditioning with 
sphingosine resulted in 68 ± 8% recovery 
of LVDP and only a 12 ± 4% infarct size. 
Since postconditioning with sphingosine, 
like  preconditioning,  involves  PKA  and 
PKG  dependent  pathways15  this  again 
reinforces  the  hypothesis  that  the  cyclic 
nucleotide-dependent  pathways  are  less 
sensitive to the effects of aging than GPCR-
dependent pathways. Postconditioning by 
sphingosine differs from GPCR-dependent 
pathways in being independent of PKC;15 
and we hypothesize that this is in part due 
to lack of reliance on PKC signaling which 
is  diminished  with  age.11  Importantly, 
these  data  reveal  that  sphingosine  is  the 
most  effective  cardioprotectant  for  aging 
rat heart and suggest that it might have the 
greater clinical relevance.
To examine other factors that could potentially contribute to 
the diminished cardioprotective capacity of GPCR pathways with 
aging, we investigated the S1P metabolic pathway. S1P levels were 
found to be generally reduced in 27 month old hearts. In view of 
the importance of S1P as an endogenous cardioprotectant,12,14-16 
this might be a contributing factor in the diminished response of 
aged hearts to ischemic pre- and postconditioning. Not only is the 
level of S1P low in aged hearts, but as discussed above, the response 
to it is also diminished. We measured the activity of SKase, the 
enzyme catalyzing the synthesis of S1P, and were surprised to find 
that the total SKase activity was not significantly different in the   
28  -month  hearts  as  compared  to  6-month  hearts. These  data 
suggest that any reduction in S1P levels in older hearts is not due 
to SKase activity but rather to other factors; perhaps increased 
S1Pase activity or an age-dependent decline in sphingosine levels.
It has been proposed that the SK1 form of SKase mediates 
prosurvival effects while SK2 is proapoptotic.23,24 This provided 
the rationale for our investigation of the ratio of SK1 to SK2 in old 
versus young hearts. We found that was even though total SKase 
activity did not change, there was a dramatic shift in the ratio of 
SK1 to SK2. SK1 activity nearly doubles with aging while SK2 
activity is halved. These are substantial changes. The data suggest 
that the activity of the two forms can be differentially regulated. 
Whether  this  shift  impacts  S1P  levels  and/or  cardioprotective 
mechanisms is not yet clear. It may be that the upregulation of 
SK1 with age is an attempt to protect against enhanced mitochon-
drial ROS formation in aged myocardium or age-related declines 
in  other  cell  signaling  components.11  Alternatively,  it  may  in 
part reflect an age-dependent increase in fibroblasts which have   
very  high  levels  of  SKase.25  If  true,  this  could  be  masking  a 
decrease in myocyte SKase.
Phospho-Akt  is  a  known  pro-survival  signaling  molecule26 
which  has  been  shown  to  be  a  key  feature  of  cardioprotective 
Figure 2. Effect of Preconditioning with Ischemia, S1P or Sphingosine on the Phosphorylation of Akt. 
Ex vivo hearts from young (Y) and old (O) rats were ischemically preconditioned (Isch-PreCond) or 
ischemically postconditioned (Isch-PostCond) as described in Methods; or pharmacologically pre- or 
post-conditioned with either 0.2 μM S1P (S1P-PreCond and S1P-PostCond) or 0.2 μM sphingosine 
(Sph-PreCond and Sph-PostCond). The index ischemia was for 40 min and full reperfusion was for 
40 min. Hearts were collected after the 40 min of reperfusion and analyzed for phospho-Akt (P-Akt) 
levels by western analysis as described in Methods. Total Akt levels are also shown (T-Akt). Controls 
consisted of non-pre- or post-conditioned hearts that underwent 30 min of equilibration, 40 min of 
ischemia and 40 min of reperfusion (EIR).Sphingosine protects aging hearts
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solution of 20 mM was prepared in ethanol and added directly 
to the perfusion buffer at a final concentration of 0.2 or 0.4 μM. 
Vehicle alone was without effect. To measure infarct size, hearts 
were sectioned, stained with triphenyltetrazolium chloride and the 
infarct area determined by computer analysis as described.19
Preparation of sub-cellular fractions and assay for sphingosine 
kinase. Rat hearts were immediately plunged into cold perfusion 
buffer  (0°C),  rapidly  blotted  dry,  weighed,  and  homogenized 
in 0.13 M KCl, 20 mM HEPES pH 7.4, 1 mM EGTA, 1 μg/l 
leupeptin, 0.25 μg/l each of aprotinin and pepstatin A plus protein 
phosphatase  inhibitors  1  and  2  (Sigma). The  homogenate  was 
either assayed directly, or in some cases subfractionated by ultracen-
trifugation into cytosolic and particulate fractions. The particulate 
fraction was washed once and the wash added back to the cytosolic 
fraction. Homogenates and cell fractions were immediately assayed 
for SKase activity. The standard assay for SKase activity has been 
described previously.20 The assay contained 5 mM ATP, 10 mM 
MgCl2, 1 μM [3H]sphingosine, 250 mM KCl, 0.05% Triton X100 
and 50 mM Tris pH 8.0. at 30°C. Measurement of S1P levels was 
conducted by combined liquid chromatography/dual tandem mass 
spectrometry (LC/MS/MS) as described previously.19
Separation of SK1 and SK2 activity. The cytosolic cell frac-
tion from each individual heart, freshly prepared, was immediately 
loaded on a rapid flow 1.8 x 50 cm Sephacryl S200 chromatography 
column and eluted with 250 mM KCl, 20 mM Tris 7.5, 1 mM 
EGTA, 1 mg/l leupeptin, 0.2 mg/l each of aprotinin and pepstatin 
A.  Elution  fractions  were  monitored  for  protein  (OD280  nm) 
and SKase activity. The SK1 and SK2 fractions were identified by 
western analysis as described previously.21 Pooled fractions were 
assayed using multiple time point measurements to obtain true 
initial rates of activity.
Western analysis. Hearts were homogenized in 0.13 M KCl,   
20  mM  HEPES  pH  7.4,  1  mM  EGTA,  1  μg/l  leupeptin,   
0.25 μg/l each of aprotinin and pepstatin A, and 1% (v/v) each of 
phosphatase inhibitor cocktails 1 and 2 (Sigma). The homogenate 
was filtered through two layers of cheesecloth to remove debris. 
Homogenates were centrifuged at 100,000 xg to generate a partic-
ulate and a cytosolic fraction. Fresh cytosol and rinsed particulate 
fractions were made 0.5% in SDS. The protein concentrations 
of  these  preparations  were  determined  using  the  Bio-Rad  DC   
(detergent-compatible)  protein  assay  against  a  BSA  standard, 
diluting  to  an  apparent  concentration  of  2  mg/ml,  and  then 
reassaying. The fractions were then diluted to a final concentra-
tion of 1 mg/ml in Laemmli buffer for SDS-polyacrylamide gel 
electrophoresis. Each lane was loaded with an equivalent amount 
of protein (generally 5 or 10 μg). Following electroblotting, the 
gel was stained with 0.1% ponceau S to visualize total protein to 
ensure that all lanes were equivalently loaded. Western analysis was 
then conducted using a rabbit antibody as described previously.15
Statistical analysis. Statistical data are expressed as mean ± stan-
dard deviation (SD). Numerical data (n ≥ 4) were compared using 
unpaired Students’s t test for a 95% confidence interval. p values 
are reported for statistical comparisons.
In conclusion, we have found that ischemic preconditioning is 
not effective in ex vivo aged hearts. Ischemic postconditioning is 
also diminished in effectiveness in aged hearts but not to the same 
extent as preconditioning. Pre- and post-conditioning with S1P are 
similarly affected in aging rat hearts. However, we have discovered 
that aged hearts respond well to sphingosine preconditioning and 
can also be effectively postconditioned with sphingosine. Thus, 
sphingosine holds promise as an effective cardioprotectant in the 
most vulnerable population, the aged.
Materials and Methods
Materials. Aprotinin, ATP, chymostatin, leupeptin, pepstatin 
A, ponceau S, protein phosphatase inhibitor cocktails, Sephacryl 
S200,  trisodium  EDTA  and  triphenyltetrazolium  chloride  were 
obtained from Sigma (St. Louis MO). D-erythro-sphingosine and 
D-erythro-sphingosine-1-phosphate  were  obtained  from  Biomol 
Research Laboratories (Plymouth Meeting PA). D-Erythro-[3-3H]-
sphingosine was obtained from American Radiolabeled Chemical 
Inc., (St. Louis MO). The rabbit Akt and phospho-Akt (ser473) 
antibodies were obtained from Cell Signaling Technology.
Langendorff ex vivo perfused heart. This study was conducted 
in accordance with the Guide for the Care and Use of Laboratory 
Animals  (National  Academic  Press,  Washington  DC,  1996). 
Rats were obtained from the Aging Rat Colony via the National 
Institute of Aging. The aging rats were on average 27-months-old 
(range 26–28 months). Young hearts were from 3- to 6-month-old 
rats.  Hearts  were  removed  under  pentobarbital  anesthesia  and 
mounted on a Langendorff apparatus as described previously.19 
Hearts  were  perfused  with  oxygenated  (95/5  O2:CO2)  Krebs-
Henseleit  solution  at  37°C.  Left  ventricular  developed  pressure 
(LVDP) was measured using a Millar micromannometer-tipped 
catheter and is reported in units of mm Hg. To measure infarct 
size, hearts were sectioned, stained with TTC and the infarct area 
determined by computer analysis.19
The protocol for non-conditioned hearts consisted of contin-
uous  perfusion  for  30  min  after  mounting  the  heart  on  the 
Langendorff apparatus (equilibration). Sustained ischemia (index 
ischemia)  was  then  induced  by  halting  perfusion  for  indicated 
lengths of time. During the index ischemia the heart was lowered 
into a thermostated chamber that maintains an ambient tempera-
ture of 37°C. This was followed by the reperfusion stage in which 
flow was again initiated for 40 min. For ischemic preconditioning, 
after 10 min of equilibration, the heart was exposed to two cycles 
of 4 min ischemia/6 min reperfusion just prior to the index isch-
emia, Pharmacologic preconditioning consisted of adding either 
S1P or sphingosine to the perfusion medium for the 30 min period 
preceding the index ischemia. For ischemic postconditioning, at 
the end of the index ischemia, reperfusion was first initiated with 
four cycles of alternating 15 sec of reperfusion/15 sec of ischemia, 
followed  by  full  reperfusion.  Pharmacologic  postconditioning 
consisted  of  adding  either  S1P  or  sphingosine  to  the  reperfu-
sion medium for the 40 min of reperfusion. To administer S1P,   
a stock solution of 2.67 mM was prepared in DMSO and 90 μl 
(for 0.4 μM final S1P concentration) was added per 600 ml of 
perfusion  buffer. To  administer  D-erythro-sphingosine,  a  stock www.landesbioscience.com Oxidative Medicine and Cellular Longevity 151
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sphingosine 1-phosphate receptors enhance adult mouse cardiac myocyte survival during 
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